- Home
- ADNT vs NVAX Comparison
ADNT vs NVAX Comparison
Compare ADNT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADNT
- NVAX
- Stock Information
- Founded
- ADNT 2016
- NVAX 1987
- Country
- ADNT Ireland
- NVAX United States
- Employees
- ADNT N/A
- NVAX N/A
- Industry
- ADNT Auto Parts:O.E.M.
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADNT Consumer Discretionary
- NVAX Health Care
- Exchange
- ADNT Nasdaq
- NVAX Nasdaq
- Market Cap
- ADNT 1.5B
- NVAX 2.0B
- IPO Year
- ADNT N/A
- NVAX 1995
- Fundamental
- Price
- ADNT $16.76
- NVAX $8.30
- Analyst Decision
- ADNT Hold
- NVAX Buy
- Analyst Count
- ADNT 9
- NVAX 6
- Target Price
- ADNT $23.50
- NVAX $17.83
- AVG Volume (30 Days)
- ADNT 1.1M
- NVAX 3.4M
- Earning Date
- ADNT 02-05-2025
- NVAX 02-26-2025
- Dividend Yield
- ADNT N/A
- NVAX N/A
- EPS Growth
- ADNT N/A
- NVAX N/A
- EPS
- ADNT 0.20
- NVAX N/A
- Revenue
- ADNT $14,688,000,000.00
- NVAX $885,193,000.00
- Revenue This Year
- ADNT N/A
- NVAX N/A
- Revenue Next Year
- ADNT $0.91
- NVAX N/A
- P/E Ratio
- ADNT $86.15
- NVAX N/A
- Revenue Growth
- ADNT N/A
- NVAX N/A
- 52 Week Low
- ADNT $16.43
- NVAX $3.53
- 52 Week High
- ADNT $37.04
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- ADNT 37.30
- NVAX 46.83
- Support Level
- ADNT $16.82
- NVAX $7.62
- Resistance Level
- ADNT $17.67
- NVAX $8.67
- Average True Range (ATR)
- ADNT 0.63
- NVAX 0.45
- MACD
- ADNT 0.00
- NVAX -0.03
- Stochastic Oscillator
- ADNT 29.34
- NVAX 40.58
About ADNT Adient plc
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.